<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282098</url>
  </required_header>
  <id_info>
    <org_study_id>NIF-14350</org_study_id>
    <secondary_id>NIF-14350</secondary_id>
    <nct_id>NCT02282098</nct_id>
  </id_info>
  <brief_title>Colchicine in Atrial Fibrillation to Prevent Stroke</brief_title>
  <acronym>CIAFS-1</acronym>
  <official_title>Targeting Inflammation in Atrial Fibrillation to Prevent Ischemic Stroke: A Feasibility Study Evaluating the Effect of Colchicine on D-dimer and Hs-CRP in Anticoagulated Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Population Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Population Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of performing a randomized&#xD;
      controlled trial to investigate the efficacy of an anti-inflammatory drug, colchicine, at&#xD;
      reducing well validated markers of thrombosis (D-dimer) and inflammation (hs-CRP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF), the most common cardiac arrhythmia (with a global burden of 33.5&#xD;
      million affected patients in 2010), is responsible for about 20% of ischemic stroke, a major&#xD;
      cause of morbidity and mortality. Anticoagulants are very effective in reducing the risk of&#xD;
      stroke in AF but on average 10-15% of treated patients still experience a stroke over a&#xD;
      10-year period and in selected elderly populations the risk is even higher. We hypothesize&#xD;
      that thrombosis mediated by inflammation might be responsible for the residual risk of&#xD;
      stroke, despite anticoagulant therapy and that targeting inflammation has the potential to&#xD;
      reduce thrombosis and the risk of stroke in anticoagulated patients with AF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">November 17, 2020</completion_date>
  <primary_completion_date type="Actual">November 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rates</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Number of eligible patients successfully randomized into study per year of study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drop-out rates</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Proportion of participants withdrawing from study for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Mean D-dimer level at baseline and Month 3 for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-CRP</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Mean level of hs-CRP at baseline and month 3 for each arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a clinically significant adverse event</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Proportion of patients with side effects such as diarrhoea, myopathy requiring drug cessation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug adherence</measure>
    <time_frame>Randomization to Month 3</time_frame>
    <description>Proportion of missing pill to dispensed pill at 6 weeks and month 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Active Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will receive colchicine 0.6 mg twice daily orally for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Colchicine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive colchicine placebo 0.6mg twice daily orally for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine</intervention_name>
    <description>Colchicine 0.6mg twice daily</description>
    <arm_group_label>Active Colchicine</arm_group_label>
    <other_name>pms-Colchicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Colchicine</description>
    <arm_group_label>Placebo Colchicine</arm_group_label>
    <other_name>Placebo Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with atrial fibrillation who has been receiving chronic anticoagulation for&#xD;
             at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to colchicine such as allergy/hypersensitivity,&#xD;
&#xD;
          -  Receiving colchicine or other anti-inflammatory drugs (such as corticosteroids,&#xD;
             methotrexate, anti-neoplastic, Interleukin 1-1b antagonist, Tumor necrosis&#xD;
             factor-alpha inhibitor),&#xD;
&#xD;
          -  Receiving food or co-medications such as strong-moderate cytochrome P450 3A4&#xD;
             inhibitors that will result in elevated plasma level of colchicine,&#xD;
&#xD;
          -  Inflammatory disorders (SLE, Rheumatoid arthritis, connective tissue disorder) or&#xD;
             chronic infection,&#xD;
&#xD;
          -  Severe renal (eGFR&lt; 30ml/min/1.73m2), or liver failure or liver aminotransferase&#xD;
             (ALT/AST &gt; 2x Upper limit of normal),&#xD;
&#xD;
          -  Moderate or severe cytopenias (platelet &lt; 100, neutrophil count &lt; 1.5) or existing&#xD;
             blood dyscrasia (e.g., myelodysplasia)&#xD;
&#xD;
          -  Pregnant or lactating woman or woman of child bearing age no protected by reliable&#xD;
             contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel Chan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Eikelboom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Population Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Population Health Research Institute</investigator_affiliation>
    <investigator_full_name>Noel Chan</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <keyword>Stroke</keyword>
  <keyword>agents, anti inflammatory</keyword>
  <keyword>D-dimer</keyword>
  <keyword>C-reactive protein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

